Samsung Biologics Launches $1.8 Billion All-Cash Bid for PolyPeptide in Peptide Manufacturing Push
The Korean CDMO giant's offer at a 40% premium to the undisturbed price targets Switzerland's leading peptide API manufacturer as demand for GLP-1 therapies reshapes the pharmaceutical supply chain.
